IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

The Uniqueness of Albumin as a Carrier in Nanodrug Delivery

Sanjivani D Mali, Yogesh B.Raut, Sanjay K. Bais
Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra
malisanjivani51@gmail.com

Abstract: *Albumin has emerged as a promising carrier in nanomedicine due to its special qualities. It is the most widely used plasma protein and has excellent non-immunogenicity, biocompatibility, biodegradability, and clinical safety. Its structural flexibility allows it to exhibit broad drug-binding capacity enhancing pharmacokinetic profiles or shielding them from rapid metabolism and clearance. Additionally, because albumin naturally interacts with receptors that are often overexpressed in diseased tissues, it actively targets pathological sites without the need for additional ligands. Because albumin exhibits a long serum alongside each semi fraction involving about 19 days this can be delivered precisely and circulated for a long time. This article describes the use of both passive and active targeting mechanisms in albumin to deliver hydrophobic drugs via nanodrug*

Keywords: Serum albumin, therapeutic delivery, nab-paclitaxel, Solvent-base paclitaxel ligand-mediated targeting, clinical investigations

I. INTRODUCTION

Nanotechnology holds significant promise in medicinal employment particularly in treatment transfer.[1]Nanomaterials have facilitated the creation connected with stage used this optimized control, safety, relocation, also precise transport associate with complex curative otherwise evaluation agents similar in the role of badly mixable formulation biomolecule also DNA sequences-based treatment within organic flow microscopic along with cytoplasmic sites.[2] nanostructures hold existed have been engineered into address that challenges of traditional drug systems to navigate living wall.[3,4] inside many cases, nanoparticles with diverse chemical compositions like oil-resin also chemical based carriers own demonstrated the ability onto regulation the distribution and release of one or more therapeutic agents while also offering strategies to overcome physiological barriers.[5,6]



Copyright to IJARSCT
www.ijarsct.co.in
DOI: 10.48175/IJARSCT-30148

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

Nanoscience exhibits considerable promise into drugs function mainly inside remedy transfer.[7] into this regard, nanoparticles have made it possible to create sophisticated platforms that allow to this capable direction, safety, relocation, also precise distribution associated with complex curative otherwise evaluation agents—similar in the role of badly mixable formulation, biomolecule also DNA sequences-based treatments—within organic flow microscopic along with cytoplasmic sites.[8] nanostructures hold existed made into address those deficiency belonging to traditional drug handover methods plus to navigate complex living wall effectively[9,10]. Moreover, nanoparticles made from diverse element formation, like oil resin and chemical-based carriers, have demonstrated the ability to regulate the distribution and release of one or more therapeutic agents while improving targeted delivery to diseased tissues.[11,12]

Plasma is related to a trio subunit: 1, 2, and 3. Every field consists of about 2 segments (A or B) with four or six alpha - coils , in turn.[13,14] That main crucial HSA attachment area to substances that are nonpolar[15,16](particularly Hydrophobic medications that are both negatively and neutrally charged are identified known as show sites I and II, respectively,[17]and placed within domains IIA or IIIA, extremely long hydrophobic compounds pockets containing arginine and lysine residues that are positively charged.[18]Specifically, site I additionally serves as referred to designate the Warfarin site due to medications like warfarin, phenylbutazone, and azapropazone attach to it. Another name for Site II is a benzodiazepine site becauseTryptophan, ibuprofen, and diazepam are examples of compounds that bind to it.[19]Thus, a number of medications, including paclitaxel and docetaxel could be sufficiently attached and then administered into location of the mass.[20]

HSA-Based Multifunctional Nanocarrier:

Due to its benefits, which include anti-immunogenicity, non-toxic, and superior biocompatibility, hybrid nanocarriers attract considerable interest for diverse molecular function. Due to their prolonged circulation duration.[21,23]They are now crucial delivery methods for many different types of pharmaceuticals, such asInorganic materials, bioactive substances, and small-molecule drugs that enhance imaging performance and efficacy of medical interventions for multiple disorders.[24] Here, we orderly enumerate that key developments made within human serum formed flexible nanocarriers during that last 5 years.

Human Serum Albumin:

Albumin in human serum consists involving 585 energy proton donors into any lone sequences.[25] Its secondary The structure is very flexible, with an α helix that is 67% and 17 six-turn disulfide bridges that serve acting as intersect binding to that the 3 section that are homologous.[26] plasma protein act as biomolecule that the liver's hepatocytes produced at approximately 9 g per date also equals a specific connected to this the bulk of prevalent (serum fraction amounts serum albumin between 3.5 and 5 g/dL15) and significant blood plasma proteins.[27] While albumin is the predominant serum albumin most protein is not in the circulation of blood.Up to 60% of protein is stored in that intermediate area.[28]

Despite having a 19-day biological half-life, it is only in circulation for 16–18 hours.[29] 16 The capillary albumin movement to flexible, as this may go back in this serum via that lymphatic system for keep serum-containing fluid levels steady concentrations of proteins.[30] Its manufacturing is controlled by the needs of the body. Specifically, that formation constituent triggered with cortisol,tetraiodothyronine along with insulin, at ailments such as low albumin levels , but potassium and exposure to chemicals can cause overly high osmotic pressure in hepatocytes.[31,32]

Additionally to activate albumin, a sufficient supply of nutrients is essential manufacturing. Actually,[33] inadequate nutrient adsorption lowers the capacity of the liver to make protein. Albumin degradation can occur into some cellular tissue, though it mostly affects hepatic and renal tissues.[34] This equilibrium among the synthesis, breakdown, or migration from the interstitial or intravascular areas establishes this efficient concentration of serum albumin. This protein is in charge of keeping the blood stable. osmotic pressure, provides nutrition to tissues, moves hormones,medications, vitamins, and divalent cations such as zinc and calcium,all over the body.[35] 17 As a scavenger of free radicals, it inflammatory disorders, and it plays a role in mechanisms such as wound healing and coagulation.[36]

Copyright to IJARSCT
www.ijarsct.co.in
DOI: 10.48175/IJARSCT-30148

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67



Figure 2:-Human Serum Albumin

Plasma albumin in different organisms

Cattle plasma represents the source of albumin, which is quite similar to the HSA.[37] 69.323 kDa is its molecule for weight, and it possesses an In water at 25 °C, its isoelectric point (pI) is 4.7, making it At a pH of neutral, negatively charged with cationically ionized under low PH environment.[38]This existence of the two adversely BSA contains both positively and negatively charged amino acids that can lead to cationic and anionic substances binding compounds.[39]As this represents easily accessible inexpensive, and widely available It has been widely utilized as a carrier for purification and control. medication delivery in the literature.[40]

Tryptophan residues are primarily give rise to intrinsic emission related to albumin, allowing HSA and BSA to be differentiated using spectrophotometric and fluorescence techniques.[41] The immunogenic response to BSAhas been extensively studied in animal models where BSA is frequently utilized one system biomolecule for investigating protein–immunological interactions.[42]In humans, contact into cattle serum albumin occurs initial into living through cow's milk consumption, meat, at through certain vaccines a pharmaceutical formulations containing bovine-derived components.[43] In a 2005 quantitative radioimmunoassay, anti-BSA IgG antibodies were identified in healthy individuals as well as cancer patients, and Western blot analysis validated their presence; however, increased anti-BSA levels showed no clear clinical symptoms in either group.[44]



Figure 3:-Plasma Albumin in different organisms

Copyright to IJARSCT
www.ijarsct.co.in
DOI: 10.48175/IJARSCT-30148

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

PREPARATION METHODS OF ALBUMIN NANOPARTICLES

Nanoparticles based on albumin can be manufactured with a variety of methods, classified into physical and chemical techniques.[45] Chemical techniques include the addition of materials such as ethanol,β-mercaptoethanol or cottonseed oil to produce nanoparticles. Heat is used in physical methods, pressure or additional physical components.[46] Typical Among the chemical methods are self-assembly, Desolvation and emulsification, whereas physical methods such as NAB-, thermal gelation, technology as well as drying by nanospray.[47]These techniques will be discussed in more depth later regularity and manufacturing are essential, as is reproducibility.[48]

1. Desolvation (Coacervation)

Among the most commonly employed techniques for producing albumin-based nanoparticles, the desolvation method is particularly notable for its simplicity and effectiveness.[49] This process involves the gradual introduction related to one drying material (e.g., dimethyl ketone or ethyl alcohol) droplet entering the in water albumin preparation below continuous mixing until turbidity appears, indicating nanoparticle formation.[50] The desolvating agents induce phase separation and protein aggregation by gradually altering the tertiary structure of the albumin framework.[51] Typically, the resulting formulation is unstable, also one pass binding representative—most often pentanedial equals included into stabilize, harden, and preserve the structure of the newly formed nanoparticles.[52]

2. Emulsification:

The process of emulsification (Figure A nonaqueous solution (oil phase) is added in 3B)[53]. into a water-phase albumin solution while being stirred, producing an unrefined emulsion.[54] Making the emulsion is possible. homogeneous through the use of any strong compression homogenization device.[55] Following which present act as approaches can be employed so reinforce that temperature based warming (temperature above 120 °C), nanoparticles,or through the use from substance any X-shape junctions (e.g.Dialdehyde) during treatment.[56]

3. Thermal Gelation:

As can be observed, thermal gelation is distinguished by heat-induced protein from Figure 3D[57]. unfolding and conformational shift, then protein- interactions between proteins, like hydrogen bonding, disulfide-sulfhydryl, hydrophobic, and electrostatic interactions exchange responses[58].The characteristics of the acquired formulation is dependent on the process's circumstances, including pH, ionic strength, protein, and concentration and ionic strength, determine the characteristics of the resulting formulation.[59,60]

4. Self-Assembly Method:

For self-assembly to occur, the albumin nanoparticle formation as a result of the rise in the Protein hydrophobicity caused by disulfide bond disruption caused by reducing or using β-mercaptoethano central alkylamine sets upon said proteins membrane brought on by adding a substance that is lipophilic.The 66-kDa protein this outcome represents this internal plasma protein aggregation along with nanoparticle development during each watery setting. This process of self-assembly is illustrated in.

5. Nanospray Drying:

As shown in Figure 3E, nanospray drying is a versatile and efficient technique frequently employed to transform a liquid feed into a dry powder form[61]. An important strength about the present process constituent which particle formation as well as drying occurs simultaneously within any one phase operation.[62] The procedure involves the atomization of a liquid solution into fine droplets, followed by their contact with heated drying gas, leading to rapid solvent evaporation and particle formation[63]. The nanospray drying mechanism generally includes several stages—feed atomization, spray-air interaction, moisture evaporation, and separation of the dried particles from the drying gas stream[64]This technique allows for precise control overview particle size, morphology, and moisture content, making it particularly suitable for fabricating albumin-based nanoparticles for pharmaceutical applications.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67



Figure 4:-Nanospray Drying

Microfluidic Mixing:

Despite being less studied,an additional method for creating albumin nanoparticles is the technology of microfluids.[65] It offers a useful substitute for making lipid [66] polymeric,[67,68]and albumin nanoparticles in serum. This method is manageable. preparation method that produces particles with adjustable sizes and a limited range of sizes.[69]Additionally, it offers a distinct opportunistic, automated, and standardized pharmaceutical manufacturing[70]. There aren't many studies in the literature on the albumin nanoparticle synthesis in a flow environment.[71]There have been positive outcomes from the study. carried out in 2020,[72]with the goal preparingDrug-loaded albumin-based nanoparticles of the core-shell type.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67



Figure 5:-Micorfluidic Mixing

II. CONCLUSION

The field of nanomedicine is growing in popularity because it offers effective and intelligent ways to deliver therapeutics for managing Irritative illnesses, cancer, with additional circumstances at recent years, Blood protein enormous promise as a medication transport platform has drawn that Numerous researchers interested among it because of its nonimmunogenicity, biodegradability, biocompatibility, and non-toxic Since it is the most prevalent, the immune system does not reject it because it is not a foreign substance. protein in the plasma, which enhances its allure.

REFERENCES

[1]. Bobo D, Robinson K Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res. 2016:33(10):2373–87.

[2]. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006:24(10):1211–17

[3]. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015:33(9):941–51.

[4]. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008:5(4):505–15.

[5]. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat Rev Drug Discov. 2014:13(9):655–72.

[6]. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010:9(8):615–27.

[7]. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007:2(1):16.

[8]. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010:9(8):615–627.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

[9]. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015:33(9):941–951.
[10]. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021:20(2):101–124.
[11]. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016:116(4):2602–2663.
[12]. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012(63):185–198.
[13]. Peters T Jr. All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego: Academic Press; 1996.
[14]. Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem. 1994:(45):153–203.
[15]. Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, Ascenzi P. The extraordinary ligand binding properties of human serum albumin. IUBMB Life. 2005:57(12):787–796.
[16]. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171–183.
[17]. He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature. 1992:358(6383):209–215.
[18]. Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol. 1975:11(6):824–832
[19]. Curry S, Mandelkow H, Brick P, Franks NP. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol. 1998:5(9):827–835.
[20]. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005:23(31):7794–7803.
[21]. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012:157(2):168–182.
[22]. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008:132(3):171–183.
[23]. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta Gen Subj. 2013:1830(12):5526–5534.
[24]. Merlot AM, Kalinowski DS, Richardson DR. Unraveling the mysteries of serum albumin—more than just a serum protein. Front Physiol. 2014:(5):299.
[25]. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng. 1999:12(6):439–446.
[26]. Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem. 1994:45:153–203.
[27]. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005:41(6):1211–1219.
[28]. Peters T Jr. All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego: Academic Press; 1996.
[29]. Rothschild MA, Oratz M, Schreiber SS. Regulation of albumin metabolism. Annu Rev Med. 1975:26:91–104.
[30]. Levick JR, Michel CC. Microvascular fluid exchange and the revised Starling principle. Cardiovasc Res. 2010:87(2):198–210.
[31]. Farrugia A. Albumin usage in clinical medicine: tradition or therapeutic? Transfus Med Rev. 2010:24(1):53–63.
[32]. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000:85(4):599–610.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

[33]. Rothschild MA, Oratz M, Schreiber SS. Regulation of albumin metabolism. Annu Rev Med. 1975:26:91–104.
[34]. Farrugia A. Albumin usage in clinical medicine: tradition or therapeutic? Transfus Med Rev. 2010:24(1):53–63.
[35]. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000:85(4):599–610.
[36]. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005:41(6):1211–1219.
[37]. Brown JR. Structural origins of bovine serum albumin. Fed Proc. 1975:34(3):591.
[38]. Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem. 1994:45:153–203.
[39]. Hirayama K, Akashi S, Furuya M, Fukuhara K. Rapid confirmation and revision of the primary structure of bovine serum albumin by ESIMS and Frit-FAB LC/MS. Biochem Biophys Res Commun. 1990:173(2):639–646.
[40]. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157(2):168–182.
[41]. Lakowicz JR, Weber G. Quenching of protein fluorescence by oxygen. Detection of structural fluctuations in proteins on the nanosecond time scale. Biochemistry. 1973:12(21):4161–4170.
[42]. Kato Y, Yamada S, Horie T, Takeda Y. Immunogenicity of bovine serum albumin and its conformational changes. Int Arch Allergy Appl Immunol. 1980:61(4):395–401.
[43]. Restani P, Ballabio C, Di Lorenzo C, Tripodi S, Fiocchi A. Molecular aspects of milk allergens and their role in clinical events. Anal Bioanal Chem. 2009:395(1):47–56.
[44]. Mäkinen-Kiljunen S, Haahtela T. Quantitation of anti-bovine serum albumin antibodies in human sera by radioimmunoassay. Int Arch Allergy Immunol. 2005:136(4):340–346.
[45]. Weber C, Kreuter J, Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm. 2000:196(2):197–200.
[46]. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003:257(1–2):169–180.
[47]. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009:2(2):59–64.
[48]. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012:157(2):168–182.
[49]. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003:257(1–2):169–180.
[50]. Weber C, Coester C, Kreuter J, Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm. 2000;196(2):197–200.
[51]. Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release. J Control Release. 2001:75(1–2):55–67.
[52]. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012:157(2):168–182
[53]. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008:132(3):171–183.
[54]. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008:60(15):1650–1662.
[55]. Marty JJ, Oppenheim RC, Speiser P. Nanoparticles—a new colloidal drug delivery system. Pharm Acta Helv. 1978:53(1):17–23.
[56]. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012:157(2):168–182.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

[57]. Clark AH, Ross-Murphy SB. Structural and mechanical properties of biopolymer gels. Adv Polym Sci. 1987:83:57–192.
[58]. Hattori M, Watanabe E, Satoh K, Okada Y, Nakai S. Heat-induced gelation of proteins: kinetics and mechanisms. J Food Sci. 1994:59(2):313–318.
[59]. Tang CH. Nanostructured soy proteins: fabrication and applications as delivery systems for bioactives. Food Hydrocoll. 2019:90:331–341.
[60]. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012:157(2):168–182.
[61]. Heng D, Lee SH, Ng WK, Tan RB. The nano spray dryer B-90. Expert Opin Drug Deliv. 2011:8(7):965–972.
[62]. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008:25(5):999–1022.
[63]. Woo MW, Daud WRW, Mujumdar AS. Spray drying of protein-rich foods: process and product quality considerations. Dry Technol. 2012:30(15):1801–1819.
[64]. Sosnik A, Seremeta KP. Advantages and challenges of nanospray drying technology for the production of drug delivery systems. Drug Dev Ind Pharm. 2015:41(4):547–554.
[65]. Capretto L, Carugo D, Mazzitelli S, Nastruzzi C, Zhang X. Microfluidic and lab-on-a-chip preparation routes for organic nanoparticles and vesicular systems for nanomedicine applications. Adv Drug Deliv Rev. 2013:65(11–12):1496–1532.
[66]. Hood RR, DeVoe DL. High-throughput continuous flow production of nanoscale liposomes by microfluidic vertical flow focusing. Small. 2015:11(43):5790–5799.
[67]. Valencia PM, Basto PA, Zhang L, Rhee M, Langer R, Farokhzad OC, Karnik R. Single-step assembly of homogenous lipid–polymeric and lipid–quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano. 2010:4(3):1671–1679.
[68]. Karnik R, Gu F, Basto P, Cannizzaro C, Dean L, Kyei-Manu W, Langer R, Farokhzad OC. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 2008:8(9):2906–2912.
[69]. Ma J, Lee SMY, Yi C, Li CW. Controllable synthesis of functional nanoparticles by microfluidic platforms for biomedical applications. Biomicrofluidics. 2017:11(2):021501.
[70]. Szita N, Boccazzi P, Zhang Z, Boyle P, Sinskey AJ, Jensen KF. Development of a multiplexed microbioreactor system for high-throughput bioprocessing. Lab Chip. 2005:5(8):819–826.
[71]. Paliwal R, Paliwal SR, Kenwat R, Kurmi BD, Sahu MK. Microfluidics-based fabrication and evaluation of albumin nanoparticles for improved delivery of anticancer drugs. Int J Biol Macromol. 2018:113:155–162.
[72]. Xu Q, Ensign LM, Lu D, Kleinstreuer C, Hanes J. Design and optimization of drug-loaded core–shell nanoparticles prepared by microfluidic co-axial flow for controlled drug delivery. J Control Release. 2020:322:122–135.

Copyright to IJARSCT
www.ijarsct.co.in
DOI: 10.48175/IJARSCT-30148